Bofutsushosan, a Japanese herbal (Kampo) medicine, attenuates progression of nonalcoholic steatohepatitis in mice

Journal of Gastroenterology

Volumn 49, Issue 6, 2014, Pages 1065-1073

  Ono, Masafumi ^a   Ogasawara, Mitsunari ^a   Hirose, Akira ^a   Mogami, Sachiko ^b   Ootake, Nobuhiro ^b   Aritake, Kosuke ^c   Higuchi, Takuma ^a   Okamoto, Nobuto ^a   Sakamoto, Shuji ^a   Yamamoto, Masahiro ^b   Urade, Yoshihiro ^c   Saibara, Toshiji ^a   Oben, Jude A ^d,e  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b TSUMURA AND CO   (Japan)

^c OSAKA BIOSCIENCE INSTITUTE   (Japan)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Adiponectin; Bofutsushosan; Kampo medicine; NAFLD

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR; AUROTHIOGLUCOSE; BOFUTSUSHOSAN; KAMPO; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BOFU-TSUSHO-SAN; HERBACEOUS AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHROPOMETRY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FATTY ACID OXIDATION; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HISTOPATHOLOGY; INSULIN RESISTANCE; INSULIN TOLERANCE TEST; LIPID DIET; LIPID METABOLISM; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ADIPOSE TISSUE; ANIMAL; C57BL MOUSE; CHINESE MEDICINE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; AUROTHIOGLUCOSE; BLOTTING, WESTERN; DIET, HIGH-FAT; DISEASE PROGRESSION; DRUGS, CHINESE HERBAL; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; LIVER; MALE; MEDICINE, KAMPO; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; REAL-TIME POLYMERASE CHAIN REACTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84902371666     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0852-8     Document Type: Article

References (37)

1. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol. 2006;101:76-82. (Pubitemid 43381712)
2. James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet. 1999;353:1634-6. (Pubitemid 29224514)
3. Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology. 2008;47:455-60. (Pubitemid 351280713)
4. Hioki C, Yoshimoto K, Yoshida T. Efficacy of bofu-tsusho-san, an oriental herbal medicine, in obese Japanese women with impaired glucose tolerance. Clin Exp Pharmacol Physiol. 2004;31:614-9. (Pubitemid 39329764)
5. Yamakawa J, Ishigaki Y, Takano F, Takahashi T, Yoshida J, Moriya J, et al. The Kampo medicines Orengedokuto, Bofutsushosan and Boiogito have different activities to regulate gene expressions in differentiated rat white adipocytes: comprehensive analysis of genetic profiles. Biol Pharm Bull. 2008;31:2083-9.
6. Shimada T, Kudo T, Akase T, Aburada M. Preventive effects of Bofutsushosan on obesity and various metabolic disorders. Biol Pharm Bull. 2008;31:1362-7. (Pubitemid 351930647)
7. Nakayama T, Suzuki S, Kudo H, Sassa S, Nomura M, Sakamoto S. Effects of three Chinese herbal medicines on plasma and liver lipids in mice fed a high-fat diet. J Ethnopharmacol. 2007;109:236-40. (Pubitemid 44959697)
8. Sakamoto S, Takeshita S, Sassa S, Zuki S, Ishikawa Y, Kudo H. Effects of colestimide and/or Bofu-tsusho-san on plasma and liver lipids in mice fed a high-fat diet. In vivo. 2005;19:1029-33.
9. Ogasawara M, Hirose A, Ono M, Aritake K, Nozaki Y, Takahashi M, et al. A novel and comprehensive mouse model of human non-alcoholic steatohepatitis with the full range of dysmetabolic and histological abnormalities induced by gold thioglucose and a high-fat diet. Liver Int. 2011;31:542-51.
10. Oike Y, Akao M, Yasunaga K, Yamauchi T, Morisada T, Ito Y, et al. Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nat Med. 2005;11:400-8. (Pubitemid 40562330)
11. Fan W, Yanase T, Nomura M, Okabe T, Goto K, Sato T, et al. Androgen receptor null male mice develop late-onset obesity caused by decreased energy expenditure and lipolytic activity but show normal insulin sensitivity with high adiponectin secretion. Diabetes. 2005;54:1000-8. (Pubitemid 40450323)
12. Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A, et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology. 2007;45:1375-81. (Pubitemid 46918321)
13. Albrecht C, Knaapen AM, Becker A, Höhr D, Haberzettl P, van Schooten FJ, et al. The crucial role of particle surface reactivity in respirable quartz-induced reactive oxygen/nitrogen species formation and APE/Ref-1 induction in rat lung. Respir Res. 2005;6:129.
14. Guerre-Millo M, Rouault C, Poulain P, André J, Poitout V, Peters JM, et al. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes. 2001;50:2809-14. (Pubitemid 33733132)
15. Ma K, Cabrero A, Saha PK, Kojima H, Li L, Chang BH, et al. Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem. 2002;277:34658-61.
16. Taniguchi CM, Ueki K, Kahn R. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest. 2005;115:718-27. (Pubitemid 40322247)
17. DeBose-Boyd RA, Ou J, Goldstein JL, Brown MS. Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands. Proc Natl Acad Sci USA. 2001;98:1477-82. (Pubitemid 32165524)
18. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004;40:46-54. (Pubitemid 38868922)
19. Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J Gastroenterol. 2008;43:811-22.
20. Tomita K, Oike Y, Teratani T, Taguchi T, Noguchi M, Suzuki T, et al. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice. Hepatology. 2008;48:458-73.
21. Rao MS, Reddy JK. PPARalpha in the pathogenesis of fatty liver disease. Hepatology. 2004;40:783-6. (Pubitemid 39288108)
22. Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu Rev Nutr. 2001;21:193-230. (Pubitemid 32695270)
23. Namikawa C, Shu-Ping Z, Vyselaar JR, Nozaki Y, Nemoto Y, Ono M, et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in nonalcoholic steatohepatitis. J Hepatol. 2004;40:781-6. (Pubitemid 38507358)
24. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45:1366-74. (Pubitemid 46918320)
25. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118:829-38. (Pubitemid 351364588)
26. Whiteman EL, Cho H, Birnbaum MJ. Role of Akt/protein kinase B in metabolism. Trends Endocrinol Metab (TEM). 2002;13:444-51. (Pubitemid 36733939)
27. Kitajima Y, Eguchi Y, Ishibashi E, Nakashita S, Aoki S, Toda S, et al. Age-related fat deposition in multifidus muscle could be a marker for nonalcoholic fatty liver disease. J Gastroenterol. 2010;45:218-24.
28. Tsuchida A, Yamauchi T, Takekawa S, Hada Y, Ito Y, Maki T, et al. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesityrelated inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes. 2005;54:3358-70. (Pubitemid 43334324)
29. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem. 2003;278:40352-63. (Pubitemid 37248604)
30. Shklyaev S, Aslanidi G, Tennant M, Prima V, Kohlbrenner E, Kroutov V, et al. Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci USA. 2003;100:14217-22. (Pubitemid 37499217)
31. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147-52. (Pubitemid 39071617)
32. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13:332-9. (Pubitemid 46376688)
33. Yano W, Kubota N, Itoh S, Kubota T, Awazawa M, Moroi M, et al. Molecular mechanism of moderate insulin resistance in adiponectin-knockout mice. Endocr J. 2008;55:515-22. (Pubitemid 351949746)
34. Endo M, Masaki T, Seike M, Yoshimatsu H. TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp Biol Med (Maywood). 2007;232:614-21. (Pubitemid 46683386)
35. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes. 2003;52:1-8. (Pubitemid 36042100)
36. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000;105:1067-75. (Pubitemid 30217691)
37. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288-95. (Pubitemid 35373562)